T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/IMT.09.61PMID 20231863PMCID PMC2837464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral tolerance

  2011cited by this paper
• Genetics of multiple sclerosis.

  2011cited by this paper
• IL-17-producing human peripheral regulatory T cells retain suppressive function.

  2009cited by this paper
• IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).

  2009cited by this paper
• Oral fingolimod (FTY720) in multiple sclerosis

  2009cited by this paper
• Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study

  2009cited by this paper
• MOG35–55 i.v suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways

  2009cited by this paper
• Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.

  2008cited by this paper
• CD11c+CD11b+ Dendritic Cells Play an Important Role in Intravenous Tolerance and the Suppression of Experimental Autoimmune Encephalomyelitis1

  2008cited by this paper
• Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens

  2008cited by this paper
• Transforming growth factor-β 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9–producing subset

  2008cited by this paper
• FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

  2008cited by this paper
• The effects of natalizumab on the innate and adaptive immune system in the central nervous system.

  2008cited by this paper
• Interleukin 4 inhibits TGF-β-induced-Foxp3+T cells and generates, in combination with TGF-β, Foxp3− effector T cells that produce interleukins 9 and 10

  2008cited by this paper
• Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-ζ Chimeric Receptor1

  2008cited by this paper
• IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Tolerization of an established αB‐crystallin‐reactive T‐cell response by intravenous antigen

  2007cited by this paper
• Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid

  2007cited by this paper
• Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey

  2007cited by this paper
• Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation.

  2007cited by this paper
• IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells

  2007cited by this paper
• Suppressive Effect of IL-27 on Encephalitogenic Th17 Cells and the Effector Phase of Experimental Autoimmune Encephalomyelitis1

  2007cited by this paper
• Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27–stimulated T cells

  2007cited by this paper
• IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways

  2007cited by this paper
• Multiple Sclerosis

  2007cited by this paper
• Azathioprine for multiple sclerosis.

  2007cited by this paper
• TH-17 cells in the circle of immunity and autoimmunity

  2007cited by this paper
• Toward the development of rational therapies in multiple sclerosis: what is on the horizon?

  2007cited by this paper
• Essential autocrine regulation by IL-21 in the generation of inflammatory T cells

  2007cited by this paper
• Type II monocytes modulate T cell–mediated central nervous system autoimmune disease

  2007cited by this paper
• A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells

  2007cited by this paper
• Risk alleles for multiple sclerosis identified by a genomewide study.

  2007cited by this paper
• IL-22 Is Expressed by Th17 Cells in an IL-23-Dependent Fashion, but Not Required for the Development of Autoimmune Encephalomyelitis1

  2007cited by this paper
• IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner*

  2007cited by this paper
• Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation

  2007cited by this paper
• Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells.

  2006cited by this paper
• Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

  2006cited by this paper
• Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

  2006cited by this paper
• Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.

  2006cited by this paper
• Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells

  2006cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Immune surveillance in multiple sclerosis patients treated with natalizumab

  2006cited by this paper
• Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes

  2006cited by this paper
• Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17–producing T cells

  2006cited by this paper
• Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

  2006cited by this paper
• Management of worsening multiple sclerosis with mitoxantrone: a review.

  2006cited by this paper
• Virus-mediated autoimmunity in Multiple Sclerosis

  2006cited by this paper
• Interleukin 18–independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation

  2006cited by this paper
• Cladribine: An Investigational Immunomodulatory Agent for Multiple Sclerosis

  2006cited by this paper
• Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study.

  2006cited by this paper
• Interleukin 27 negatively regulates the development of interleukin 17–producing T helper cells during chronic inflammation of the central nervous system

  2006cited by this paper
• TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.

  2006cited by this paper
• Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis

  2005cited by this paper
• Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging.

  2005cited by this paper
• IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

  2005cited by this paper
• Immunology of multiple sclerosis.

  2005cited by this paper
• Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.

  2005cited by this paper
• A paradoxical role of APCs in the induction of intravenous tolerance in experimental autoimmune encephalomyelitis.

  2005cited by this paper
• Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity

  2005cited by this paper
• Mitoxantrone for multiple sclerosis.

  2005cited by this paper
• Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.

  2005cited by this paper
• Oral tolerance

  2005cited by this paper
• Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide— mechanisms independent of pyrimidine depletion

  2004cited by this paper
• Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta.

  2004cited by this paper
• Early administration of IL-12 suppresses EAE through induction of interferon-gamma.

  2004cited by this paper
• Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo.

  2004cited by this paper
• Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

  2004cited by this paper
• Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis

  2004cited by this paper
• Mechanism of action of mitoxantrone

  2004cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis

  2004cited by this paper
• Limited repertoire of HLA-DRB1*0401-restricted MBP111-129-specific T cells in HLA-DRB1*0401 Tg mice and their pathogenic potential.

  2004cited by this paper
• Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody

  2004cited by this paper
• FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function

  2004cited by this paper
• Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

  2003cited by this paper
• Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17*

  2003cited by this paper
• The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta.

  2003cited by this paper
• Recombinant TCR Ligand Induces Tolerance to Myelin Oligodendrocyte Glycoprotein 35-55 Peptide and Reverses Clinical and Histological Signs of Chronic Experimental Autoimmune Encephalomyelitis in HLA-DR2 Transgenic Mice1

  2003cited by this paper
• Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment

  2003cited by this paper
• First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients.

  2002cited by this paper
• Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.

  2002cited by this paper
• Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients.

  2002cited by this paper
• Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

  2002cited by this paper
• EncephalomyelitisExperimental Autoimmune System Inflammation During Active Immune Responses and Central Nervous Cells Suppress Antigen-Specific Autoreactive Regulatory T + CD25+ Cutting Edge: CD4

  2002cited by this paper
• IL-12p35-Deficient Mice Are Susceptible to Experimental Autoimmune Encephalomyelitis: Evidence for Redundancy in the IL-12 System in the Induction of Central Nervous System Autoimmune Demyelination1

  2002cited by this paper
• TCR Peptide Therapy in Human Autoimmune Diseases

  2001cited by this paper
• Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions

  2001cited by this paper
• Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells.

  2001cited by this paper
• Mechanisms of action of glatiramer acetate in multiple sclerosis

  2001cited by this paper
• Mechanisms of suppression of experimental autoimmune encephalomyelitis by intravenous administration of myelin basic protein: role of regulatory spleen cells.

  2000cited by this paper
• Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

  2000cited by this paper
• Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction

  2000cited by this paper
• Elevated CD40 Ligand Expressing Blood T‐Cell Levels in Multiple Sclerosis Are Reversed by Interferon‐Beta Treatment

  2000cited by this paper
• Cladribine and progressive MS

  2000cited by this paper
• Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.

  2000cited by this paper
• Functional Responses and Costimulator Dependence of Memory CD4+ T Cells1

  2000cited by this paper
• Mechanisms of immunomodulation by glatiramer acetate

  2000cited by this paper
• Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing--remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide.

  2000cited by this paper
• The genetics of multiple sclerosis.

  2000cited by this paper

• COVID‐19 immunopathology with emphasis on Th17 response and cell‐based immunomodulation therapy: Potential targets and challenges

  2021cites this paper
• Rituximab for acute demyelinating myelopathy after allogeneic hematopoietic stem cell transplantation: a case report

  2020cites this paper
• The tale of histone modifications and its role in multiple sclerosis

  2018cites this paper
• Early Markers of Microglia Activation in Inflammatory Diseases

  2017cites this paper
• Exploring the role of hypoxia in neuroinflammatory disease and the use of oxygen as a therapy

  2017cites this paper
• Targeting molecules involved in immune cell trafficking to the central nervous system for therapy in multiple sclerosis

  2017cites this paper
• The Assessment of Sexual Dysfunction in Male Patients with Multiple Sclerosis.

  2017cites this paper
• Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications

  2017cites this paper
• Role of IRF4-Mediated Inflammation: Implication in Neurodegenerative Diseases.

  2017cites this paper
• SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the Th17/Treg Balance

  2017cites this paper
• SH479, a Betulinic Acid Derivative, Ameliorates Experimental Autoimmune Encephalomyelitis by Regulating the T Helper 17/Regulatory T Cell Balance

  2017cites this paper
• The Potential Role of T Helper Cell 22 and IL-22 in Immunopathogenesis of Multiple Sclerosis.

  2016cites this paper
• In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis.

  2016cites this paper
• Therapeutic Advances in Neurological Disorders

  2016cites this paper
• Emerging immunopharmacological targets in multiple sclerosis.

  2015cites this paper
• Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications

  2015cites this paper
• Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid.

  2014cites this paper
• CD28 ligation in the absence of TCR stimulation up-regulates IL-17A and pro-inflammatory cytokines in relapsing-remitting multiple sclerosis T lymphocytes.

  2014cites this paper
• Protective Effect of Cytosolic Phospholipase A2 Inhibition against Inflammation and Degeneration by Promoting Regulatory T Cells in Rats with Experimental Autoimmune Encephalomyelitis

  2014cites this paper
• Protein 4.1R attenuates autoreactivity in experimental autoimmune encephalomyelitis by suppressing CD4(+) T cell activation.

  2014cites this paper
• Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.

  2014cites this paper
• Peripheral blood CD8αα+CD11c+MHC−II+CD3- cells attenuate autoimmune glomerulonephritis in rats

  2013cites this paper
• Clinical features of Chinese patients with multiple sclerosis with aquaporin-4 antibodies in cerebrospinal fluid but not serum.

  2013cites this paper
• Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis

  2013cites this paper
• Citrullination of Histone H3 Interferes with HP1-Mediated Transcriptional Repression

  2012cites this paper
• Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.

  2012cites this paper
• Multiple sclerosis and sexual dysfunction.

  2012cites this paper
• Neuroantigen-specific, tolerogenic vaccines: GM-CSF is a fusion partner that facilitates tolerance rather than immunity to dominant self-epitopes of myelin in murine models of experimental autoimmune encephalomyelitis (EAE)

  2011cites this paper
• Suppression of human CD4+ T cell activation by 3,4-dimethoxycinnamonyl-anthranilic acid (tranilast) is mediated by CXCL9 and CXCL10.

  2011cites this paper
• EAE: imperfect but useful models of multiple sclerosis.

  2011cites this paper
• Exploring the molecular basis to the regulatory effects of Cannabinoids on toll-like receptor signalling

  2010cites this paper